SETTING: Low-dose recombinant human interleukin 2 (rhuIL-2) adjunctive immunotherapy in multidrug resistant tuberculosis (MDR-TB) patients. OBJECTIVE: Evaluation of the effects of daily versus pulse-administered rhuIL-2 compared to placebo. DESIGN: MDR-TB patients on best available antituberculous chemotherapy received rhuIL-2 for 30 consecutive days (daily therapy), or for 5 days followed by a 9-day 'rest', for three cycles (pulse therapy). Placebo control patients received diluent. The cumulative total dose of rhuIL-2 given to each patient in either rhuIL-2 treatment group was the same. Patient immunologic, microbiologic, and radiologic responses were compared. RESULTS: The three treatment schedules induced different results. Immune activation was documented in patients receiving daily rhuIL-2 therapy. Numbers of CD25+ and CD56+ cells in the peripheral blood were increased in these patients, but not in patients receiving pulse rhuIL-2 or placebo. In addition, 5/8 (62%) patients receiving daily rhuIL-2 demonstrated reduced or cleared sputum bacterial load while only 2/7 (28%) pulse rhuIL-2 treated and 2/8 (25%) controls showed bacillary clearance. Chest radiographs of 7/12 (58%) patients receiving daily rhuIL-2 indicated significant improvement over 6 weeks. Only 2/9 (22%) pulse rhuIL-2-treated patients and 5/12(42%) placebo controls showed radiologic improvement. CONCLUSION: Daily low dose rhuIL-2 adjunctive treatment stimulates immune activation and may enhance the antimicrobial response in MDR-TB.
RCT Entities:
SETTING: Low-dose recombinant humaninterleukin 2 (rhuIL-2) adjunctive immunotherapy in multidrug resistant tuberculosis (MDR-TB) patients. OBJECTIVE: Evaluation of the effects of daily versus pulse-administered rhuIL-2 compared to placebo. DESIGN: MDR-TB patients on best available antituberculous chemotherapy received rhuIL-2 for 30 consecutive days (daily therapy), or for 5 days followed by a 9-day 'rest', for three cycles (pulse therapy). Placebo control patients received diluent. The cumulative total dose of rhuIL-2 given to each patient in either rhuIL-2 treatment group was the same. Patient immunologic, microbiologic, and radiologic responses were compared. RESULTS: The three treatment schedules induced different results. Immune activation was documented in patients receiving daily rhuIL-2 therapy. Numbers of CD25+ and CD56+ cells in the peripheral blood were increased in these patients, but not in patients receiving pulse rhuIL-2 or placebo. In addition, 5/8 (62%) patients receiving daily rhuIL-2 demonstrated reduced or cleared sputum bacterial load while only 2/7 (28%) pulse rhuIL-2 treated and 2/8 (25%) controls showed bacillary clearance. Chest radiographs of 7/12 (58%) patients receiving daily rhuIL-2 indicated significant improvement over 6 weeks. Only 2/9 (22%) pulse rhuIL-2-treated patients and 5/12(42%) placebo controls showed radiologic improvement. CONCLUSION: Daily low dose rhuIL-2 adjunctive treatment stimulates immune activation and may enhance the antimicrobial response in MDR-TB.
Authors: Isabel Sada-Ovalle; Markus Sköld; Tian Tian; Gurdyal S Besra; Samuel M Behar Journal: Am J Respir Crit Care Med Date: 2010-05-27 Impact factor: 21.405
Authors: Crystal Y Chen; Dan Huang; Shuyu Yao; Lisa Halliday; Gucheng Zeng; Richard C Wang; Zheng W Chen Journal: J Immunol Date: 2012-04-02 Impact factor: 5.422
Authors: U Seitzer; K Kayser; H Höhn; P Entzian; H H Wacker; S Ploetz; H D Flad; J Gerdes; M J Maeurer Journal: Immunology Date: 2001-11 Impact factor: 7.397
Authors: Andre L Moreira; Liana Tsenova; Melles Haile Aman; Linda-Gail Bekker; Sherry Freeman; Bande Mangaliso; Ulf Schröder; Jaishree Jagirdar; William N Rom; Michael G Tovey; Victoria H Freedman; Gilla Kaplan Journal: Infect Immun Date: 2002-04 Impact factor: 3.441
Authors: Brian Abel; Michele Tameris; Nazma Mansoor; Sebastian Gelderbloem; Jane Hughes; Deborah Abrahams; Lebohang Makhethe; Mzwandile Erasmus; Marwou de Kock; Linda van der Merwe; Anthony Hawkridge; Ashley Veldsman; Mark Hatherill; Giulia Schirru; Maria Grazia Pau; Jenny Hendriks; Gerrit Jan Weverling; Jaap Goudsmit; Donata Sizemore; J Bruce McClain; Margaret Goetz; Jacqueline Gearhart; Hassan Mahomed; Gregory D Hussey; Jerald C Sadoff; Willem A Hanekom Journal: Am J Respir Crit Care Med Date: 2010-02-18 Impact factor: 21.405
Authors: David J C Miles; Marianne van der Sande; Sarah Crozier; Olubukola Ojuola; Melba S Palmero; Mariama Sanneh; Ebrima S Touray; Sarah Rowland-Jones; Hilton Whittle; Martin Ota; Arnaud Marchant Journal: Clin Vaccine Immunol Date: 2008-04-09